Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
52 Results for "
complex V
" in MedChemExpress (MCE) Product Catalog:
Products (52)
52 Results for "complex V" in MCE Product Catalog:
Cat. No.: HY-P78753
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: CD3G; T3G; CD3 Gamma Subunit Of T-Cell Receptor complex; T-Cell Antigen Receptor complex, Gamma Subunit Of T3; T-Cell Surface Glycoprotein CD3 Gamma Chain; CD3g Molecule, Epsilon (CD3-TCR complex); T-Cell Receptor T3 Gamma Chain; TCR Ti Gamma-Chain V8-J2
Species:
Human
Source:
HEK293
Cat. No.: HY-P71845
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: CD3G; T3G; CD3 Gamma Subunit Of T-Cell Receptor complex; T-Cell Antigen Receptor complex, Gamma Subunit Of T3; T-Cell Surface Glycoprotein CD3 Gamma Chain; CD3g Molecule, Epsilon (CD3-TCR complex); T-Cell Receptor T3 Gamma Chain; TCR Ti Gamma-Chain V8-J2
Species:
Cynomolgus
Source:
P. pastoris
Cat. No.: HY-184896
CAS No.: 3032314-99-8
Target:
Molecular Glues Eukaryotic Release Factor (eRF) c-Myc Androgen Receptor Kallikrein Ser/Thr Protease E1/E2/E3 Enzyme
Research Areas:
XYD113 is an orally active, selective GSPT1 Molecular glue degrader. XYD113 promotes the formation of the CRBN-GSPT1 ternary complex and mediates GSPT1 degradation in a CRBN-dependent manner via the ubiquitin-proteasome system. XYD113 downregulates genes associated with the occurrence and progression of prostate cancer (c-Myc, AR, AR-V7, KLK3, KLK2, TMPRSS2). XYD113 exhibits anticancer activity against prostate cancer. XYD113 can be used in the research of prostate cancer .
Cat. No.: HY-W854844
CAS No.: 2913587-30-9
Research Areas:
JP-2-196 is a molecular glue that covalently targets the RING family E3 ligase RNF126. JP-2-196 also binds to RNF40, MID2, RNF219, RNF14, and LRSAM1. JP-2-196 induces the formation of ternary complexes between RNF126 and target proteins (e.g., BRD4, AR-V7), thereby promoting their ubiquitination and proteasomal degradation. JP-2-196 has potential for cancer research (such as prostate cancer and leukemia) .
Cat. No.: HY-181883
KRAS-IN-55 is a pan-KRAS inhibitor with IC50 values of 4.3, 9.6 and 1.6 nM against KRAS G12C, KRAS G12D and KRAS G12V, respectively. KRAS-IN-55 induces the formation of a new binding pocket on KRAS, thereby forming a high-affinity ternary complex with cyclophilin A (CYPA), inhibiting the interactions of KRAS with downstream effectors RAF and PI3K, and blocking oncogenic MAPK and PI3K signaling pathways. KRAS-IN-55 is applicable to cancer research such as colorectal cancer and non-small cell lung cancer .
Cat. No.: HY-P1733A
Synonyms: BMF-Y TFA
Target:
Research Areas:
BMf-BH3 TFA (BMF-Y TFA) is a pro-apoptotic (apoptosis) protein containing only the BH3 domain, and also serves as a cellular stress sentinel for actin cytoskeleton signaling. BMf-BH3 TFA binds to pro-survival Bcl-2 family members via its BH3 domain to block their anti-apoptotic functions. BMf-BH3 TFA can be used in cancer-related research .
Cat. No.: HY-156498R
CAS No.: 2765082-12-8
Research Areas:
RMC-7977 (Standard) is the analytical standard of RMC-7977 (HY-156498). This product is intended for research and analytical applications. RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRAS G12C cancer models, and demonstrates good tolerability across various RAS cancer models .
Cat. No.: HY-P705321
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A; MHC Class 1 Antigen; Major Histocompatibility complex, Class I, A; MHC ClassI Antigen; HLA Class I Histocompatibility Antigen, A Alpha Chain; Lymphocyte Antigen; MHC Class I Antigen HLA-A Heavy Chain; HLA-A*6602 Antigen; Leukocyte Antigen Class I-A
Species:
Human
Source:
HEK293
Cat. No.: HY-P705322
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A; MHC Class 1 Antigen; Major Histocompatibility complex, Class I, A; MHC ClassI Antigen; HLA Class I Histocompatibility Antigen, A Alpha Chain; Lymphocyte Antigen; MHC Class I Antigen HLA-A Heavy Chain; HLA-A*6602 Antigen; Leukocyte Antigen Class I-A
Species:
Human
Source:
HEK293
Cat. No.: HY-P705357
Purity: ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: HLA-A; MHC Class 1 Antigen; Major Histocompatibility complex, Class I, A; MHC ClassI Antigen; HLA Class I Histocompatibility Antigen, A Alpha Chain; Lymphocyte Antigen; MHC Class I Antigen HLA-A Heavy Chain; HLA-A*6602 Antigen; Leukocyte Antigen Class I-A
Species:
Human
Source:
HEK293
Cat. No.: HY-P706076
Purity: ≥ 85%, as determined by reducing SDS-PAGE.
Synonyms: MAP2K1; MAPKK1; Prev. PRKMK1; MAPKK 1; Dual Specificity Mitogen-Activated Protein Kinase Kinase 1; MEK 1; MAPK/ERK Kinase 1; Protein Kinase, Mitogen-Activated, Kinase 1 (MAP Kinase Kinase 1); MEK1; CFC3; MKK1; MEL; ERK Activator Kinase 1; Mitogen-Activated Protein Kinase Kinase 1; MAP Kinase Kinase 1; RAF1; Raf Proto-Oncogene Serine/Threonine Protein Kinase; Raf-1 Proto-Oncogene, Serine/Threonine Kinase; Non-Specific Serine/Threonine Protein Kinase; Raf-1; Eosinophil Cationic Protein; RAF Proto-Oncogene Serine/Threonine-Protein Kinase; Ribonuclease 3; Proto-Oncogene C-RAF; Oncogene RAF1; C-Raf; CMD1NN; CRAF; RNASE3; V-Raf-1 Murine Leukemia Viral Oncogene Homolog 1; CRaf; C-Raf Proto-Oncogene, Serine/Threonine Kinase; NS5; V-Raf-1 Murine Leukemia Viral Oncogene-Like Protein 1; RAF
Species:
Human
Source:
Sf9 insect cells
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
